FDA Approves Weekly Leqembi Shot as Alternative to IV Infusions for Alzheimer's

The FDA has approved a once-weekly self-injectable form of Leqembi, giving early Alzheimer's patients a home-based alternative to clinic IV infusions.

Alzheimer's patients who previously had to visit infusion clinics every two weeks can now start treatment with a once-weekly injection administered under the skin, following FDA approval on July 13, 2026. The agency cleared a supplemental Biologics License Application (sBLA) for lecanemab-irmb — sold as Leqembi Iqlik — in its new subcutaneous formulation, developed by Eisai and its partner BioArctic AB, a Swedish biotech listed on Nasdaq Stockholm. Leqembi was originally approved in its intravenous form for early Alzheimer's disease, targeting amyloid plaques in the brain. The newly approved subcutaneous version is intended as a starting-dose option, meaning patients can begin therapy with the self-injection rather than requiring IV administration first. The approval was announced from Stockholm, where BioArctic is headquartered, reflecting the joint development partnership between the Japanese pharmaceutical company Eisai and the Swedish firm. Leqembi belongs to a class of anti-amyloid antibody treatments that have represented a significant shift in Alzheimer's care over recent years.

Why it matters

A self-injectable format removes the need for repeated clinic visits for IV infusions, potentially making one of the few approved disease-modifying Alzheimer's treatments more accessible and convenient for patients and caregivers. This could meaningfully expand the number of people able to sustain long-term treatment.

What's next

It is not yet clear when Leqembi Iqlik in its subcutaneous form will be commercially available or how it will be priced relative to the existing IV formulation.

Key facts

• FDA approved the subcutaneous form of lecanemab-irmb (Leqembi Iqlik) on July 13, 2026
• The new formulation is administered once weekly via injection under the skin
• The original IV formulation required clinic visits every two weeks
• The drug is developed jointly by Eisai (Japan) and BioArctic AB (Sweden, Nasdaq Stockholm: BIOA B)
• Approval came via a supplemental Biologics License Application (sBLA), not a new drug application
• The subcutaneous version is approved as a starting dose for early Alzheimer's disease

Bias & framing notes

Both sources appear to reproduce the same Cision/PRNewswire press release verbatim, originating from BioArctic and Eisai — meaning the reporting is essentially a company announcement rather than independent journalism. The facts about the FDA approval are reliable as a regulatory event, but the framing is entirely from the manufacturers' perspective, with no independent clinical commentary or patient advocacy input present.

NewsClear — neutral news & congressional tracking · Bill of the Week